Synthesis and Application of New Structural Well Defined Branched Polymers as Conjugating Agents for Peptides

• US 20090240028A1
• Filed: 11/24/2008
• Published: 09/24/2009
• Est. Priority Date: 08/08/2003
• Status: Abandoned Application

• Current Assignee: Novo Nordisk A/S
• Original Assignee: Novo Nordisk A/S
• Inventors: Kodra, Janos Tibor, Lau, Jesper, Hansen, Thomas Kruse, Dorwald, Florencio Zaragoza, Bloch, Paw, Behrens, Carsten, Kofod-Hansen, Mikael
• Application Number:
  US12/276,885
• Publication Number:
  US 20090240028A1
• Time in Patent Office: Days
• US Class Current: 530/324
• CPC Class Codes: A61K 47/549 Sugars, nucleosides, nucleotides or nucleic acids
• CPC Class Codes: A61K 47/60 the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
• CPC Class Codes: C12N 9/6437 Coagulation factor VIIa (3.4.21.21)
• CPC Class Codes: C12P 21/005 Glycopeptides, glycoproteins

Abstract

The invention provides synthesis and application of new structural well defined branched polymers as protraction agents for peptide and protein.

Claims

1. A conjugate comprising a dendrimer covalently attached to a peptide wherein the conjugate has an in vivo half life that is improved by at least 10% as compared to the peptide.

2. The conjugate of claim 1, wherein the conjugate comprises a structure represented by the formula:

((dendrimer)-(L3)_0-1)_z-(peptide),

wherein the L3 is a linking moiety, and z is an integer≧

1 representing the number of dendrimers conjugated to the peptide.

3. The conjugate of claim 2, wherein L3 represents a divalent radical or valence bonds.

4. The conjugate of claim 3, wherein L3 wherein the divalent radical is alkylene, alkenylene, alkynylene, a divalent aromatic group, a divalent partly or fully saturated cycloalkyl group, a sulfur or oxygen atom, alkyleneoxy, alkylenethio, alkenyleneoxy, alkenylenethio, alkynyleneoxy, or alkynylenethio.

5. The conjugate of claim 2, wherein L3 is 1,2-ethandiyl;

1,3-propandiyl;

1,4-butandiyl;

1,5-pentandiyl;

1,6-hexandiyl;

(CH₂CH₂O—

)_n, where n is an integer between 0 and 10;

—

(CR¹R²—

CR³R⁴—

O)_n—

, where n is an integer between 0 and 10 and R¹, R², R³ and R⁴ independently can be hydrogen or C_1-6alkyl;

or ((CH₂)_mO)_n—

, where m is 2, 3, 4, 5, 6, and n is an integer between 0 and 10.

6. The conjugate of claim 1, wherein the conjugate comprises a dendrimer having a molecular weight of above 1 kDa.

7. The conjugate of claim 6, wherein the conjugate comprises a dendrimer having a molecular weight of above 3 kDa.

8. The conjugate of claim 7, wherein the conjugate comprises a dendrimer having a molecular weight of above 5 KDa.

9. The conjugate of claim 1, wherein the dendrimer has a molecular weight of below 10 kDa.

10. The conjugate of claim 9, wherein the dendrimer has a molecular weight of below 7 kDa.

11. The conjugate of claim 1, wherein the conjugate has an isoelectric point between 3 and 7.

12. The conjugate of claim 1, wherein the conjugate has a net negative charge under physiological conditions.

13. The conjugate of claim 1, wherein the dendrimer is attached to the peptide via an residue which has been added, derivatized, and/or substituted into the peptide.

14. The conjugate of claim 1, wherein the dendrimer is attached to the peptide via a modified glycan moiety.

15. The conjugate of claim 14, wherein the dendrimer is attached to the glycan moiety of a glycoprotein via aldehyde functionalities obtained by selective oxidation of the glycan moiety.

16. The conjugate of claim 15, wherein the dendrimer is attached to the peptide via an oxidised N- or O-glycan moiety.

17. The conjugate of claim 1, wherein the dendrimer is attached via reactive aldehydes on the peptide and oxime, hydrazine, or hydrazide on the dendrimer.

18. The conjugate of claim 1, wherein the peptide is selected from the group consisting of:

aprotinin, tissue factor pathway inhibitor or other protease inhibitors, insulin or insulin precursors, human or bovine growth hormone, interleukin, glucagon, GLP-1, GLP-2, IGF-I, IGF-II, tissue plasminogen activator, transforming growth factor α

or β

, platelet-derived growth factor, GRF (growth hormone releasing factor), an immunoglobulin, EPO, TPA, protein C, a blood coagulation factor, exendin-3, exentidin-4, or a functional analogue of any thereof.

19. The conjugate of claim 18, wherein the peptide is GLP-2.

20. The conjugate of claim 18, wherein the peptide is a blood coagulation factor selected from FVII, FVIII, FIX, and FXIII, or an analogue of any thereof.

21. The conjugate of claim 20, wherein the peptide is FVIII or an analogue thereof.